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Chemokine receptors play important roles in the immune system and are linked to several
human diseases. Targeting chemokine receptors have so far shown very little success
owing to, to some extent, the promiscuity of the immune system and the high degree of
biased signaling within it. CCR7 and its two endogenous ligands display biased signaling
and here we investigate the differences between the two ligands, CCL21 and CCL19,
with respect to their biased activation of CCR7. We use bystander bioluminescence
resonance energy transfer (BRET) based signaling assays and Transwell migration assays
to determine (A) how swapping of domains between the two ligands affect their signaling
patterns and (B) how receptor mutagenesis impacts signaling. Using chimeric ligands we
find that the chemokine core domains are central for determining signaling outcome as
the lack of β-arrestin-2 recruitment displayed by CCL21 is linked to its core domain and
not N-terminus. Through a mutagenesis screen, we identify the extracellular domains
of CCR7 to be important for both ligands and show that the two chemokines interact
differentially with extracellular loop 2 (ECL-2). By using in silico modeling, we propose a
link between ECL-2 interaction and CCR7 signal transduction. Our mutagenesis study
also suggests a lysine in the top of TM3, K1303.26, to be important for G protein signaling,
but not β-arrestin-2 recruitment. Taken together, the bias in CCR7 between CCL19 and
CCL21 relies on the chemokine core domains, where interactions with ECL-2 seem
particularly important. Moreover, TM3 selectively regulates G protein signaling as found
for other chemokine receptors.
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INTRODUCTION
The chemokine receptor CCR7 and its two endogenous ligands,
CCL21 and CCL19, are involved in the lymph node homing of
several T cell subpopulations and antigen-presenting dendritic
cells (DC), which is central for the DC priming of T cells for
antigen-specific activation (1). The system is an example of ligand
bias (2, 3), where the two agonists elicit differential signaling
patterns through the same receptor. Two other forms of bias
exist, namely receptor bias and tissue bias (3, 4). At CCR7,
CCL19 and CCL21 both induce G protein signaling, whereas
only CCL19 induces β-arrestin-2 recruitment leading to receptor
internalization and recycling (5–7). CCL21, on the other hand,
has been found to induce much stronger ERK phosphorylation
than CCL19 (7).
Chemokine receptors belong to the large G protein-coupled
receptor (GPCR) superfamily, a diverse group in which the
receptors respond to a variety of ligand types and are involved
in a wide range of physiological processes. Chemokines are
8–12 kD peptides and larger than the ligands of many other
GPCRs (8). In contrast to small molecules, which can bind
very deep in the binding pocket (9), chemokines mainly interact
with the extracellular domains of the receptor (8). Since GPCRs
play a central role in so many different physiological systems
they constitute a highly interesting group of therapeutic targets,
this is why a lot of research focuses on the understanding
of their activity. Thus, the receptor family makes up a large
part of the drug targets for approved drugs and compounds
currently undergoing clinical investigation (10, 11). Where
GPCRs at first were perceived to either adopt an active or inactive
conformation, it is now widely accepted that the receptors are
much more dynamic, existing in several intermediate states and
that several distinct active conformations exist each leading
to distinct functional outcomes depending on the ligand it
interacts with (12–16). Studies have identified distinct areas
selectively important for G protein signaling (17–19) or β-
arrestin-2 recruitment (20, 21). These studies indicate that
individual receptor domains might couple to different signaling
pathways independently (4). Thus, targeting of GPCRs can
potentially become more effective by targeting the signaling
events underlying a specific physiological effect while limiting
unwanted side effects. Agonist interactions leading to receptor
activation has also been studied in great detail (22) and
information of the molecular interactions between one of several
agonists with a given receptor could provide a foundation for the
manipulation of receptor signaling in a therapeutic setting.
From crystal structures and mutagenesis studies it
seems that the chemokine N-terminus enters the receptor
by interactions with TM2 in the minor binding pocket
[delimited by TM1-3 and−7 (23)], where several central
activation initiation interaction residues have been identified
(23–26). However, although potentially entering the receptor
by a common entry site, different chemokines show diverse
utilization of the binding pocket, with some filling the
pocket completely (26) and others showing a confinement
to the minor binding pocket only (27, 28). Such differential
utilization of the binding pocket may also apply for the two
ligands interacting with CCR7, for which we have previously
identified mutations in the major binding pocket affecting
only CCL21-induced, but not CCL19-induced G protein
signaling (7).
Studies from the 1990’s, covering chemokine—receptor
interactions, led to the proposition of a so-called two-step
activation model describing how a chemokine interacts with its
receptor in both a temporal and functional (two-step) and a
spatial (two-site) manner (8, 24, 29–31). The first step consist
of interactions between the chemokine core domain and the
extracellular domains of the receptor, referred to as chemokine
recognition site 1 (CRS1), in a process which is thought to
confer high affinity without inducing receptor activation. Instead,
the receptor activation takes place during the second step;
this often includes interactions of the flexible chemokine N-
terminus with the transmembrane domains of the receptor, a
site referred to as second chemokine recognition site (CRS2).
More recent functional studies and novel crystal structures
show that this two-step model is too simple to explain the
complex chemokine receptor activation mechanism and several
additional interaction sites have been presented and found
relevant for chemokine receptor activation (24, 32). However,
both the original two-step activation model and its newer
updated versions along with studies of chemokine N-termini
(33) all suggest that the chemokine N-terminus is central for
receptor activation.
In the current study, we investigate the role of the N-terminus
and the core domains of CCL21 and CCL19 with regard to the
differential signaling pattern of the two chemokines in CCR7
activation. Moreover, we describe CCR7 regions of selective
importance for both CCL19 and CCL21. Finally, we identify a
region in CCR7 of selective importance for G protein signaling,
but not β-arrestin-2 recruitment. Altogether these observations
pave the way for future selective targeting of not only one of
many chemokines interacting with the same receptor, but also
for selective drugs targeting one among a subset of signaling
pathways initiated upon agonist binding to its receptor.
MATERIALS AND METHODS
Human Chemokines
The human chemokines CCL19 (catalog No. 361-MI) and
CCL21 (catalog No. 366-6C) were purchased from R&D
Systems (Minneapolis, MN, USA) or PeproTech (LuBioScience,
Luzern, Switzerland).
Expression and Purification of the Human
Chimeric CCL19CCL21N-term and
CCL21CCL19N-term Chemokines
The CCL21CCL19N−term chimera was expressed and purified
as described in detail in Jørgensen et al. (34), while the
CCL19CCL21N−term chimera was expressed and purified as
described in detail for the chemokine CCL19 in Veldkamp et al.
(35). The CCL21CCL19N−term chimera contains residues 1–16 of
human CCL19 and residues 17–111 of human CCL21 resulting
in the protein sequence below:
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GTNDAEDCCLSVTQKPIPAKVVRSYRKQEPSLGCSIPAI
LFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPA
QGCRKDRGASKTGKKGKGSKGCKRTERSQTPKGP.
The CCL19CCL21N−term chimera consists of residues 1–16 of
human CCL21 in place of the same numbered residues in human
CCL19 resulting in the protein sequence below.
SDGGAQDCCLKYSQRKIPGYIVRNFHYLLIKDGCRVPAV
VFTTLRGRQLCAPPDQPWVERIIQRLQRTSAKMKRRSS.
As described in Veldkamp et al. (36) protein identity was
verified by mass spectrometry and one-dimensional NMR
spectra of the chimeras were consistent with that of a
folded chemokine.
Mutagenesis
The human CCR7 wild-type cDNA was cloned from a spleen-
derived cDNA library. Mutations were introduced into the
CCR7 WT pcDNA 3.1+ expression vector by PCR using
the QuickChangeTM site-directed mutagenesis kit according to
the manufacturer’s instructions (Stratagene, La Jolla, CA). All
mutations were verified by DNA sequence analysis.
Cell Culturing and Transfection
CHO-k1 cells were grown at 5% CO2 at 37
◦C in RPMI
supplemented with 10% FBS, 180 U/ml penicillin, and 45µg/ml
streptomycin. Transient transfection of cells used in the BRET
assays was performed using the Lipofectamine R© 2000 method
(Invitrogen) as described by the manufacturers. Briefly, 500,000
cells were seeded in a 6-well plate 1 day before transfection. Cells
were transfected with 1µg DNA in a ratio of 1:5 receptor:Camyel
reporter construct (37), for the cAMP accumulation assay,
whereas cells used in the β-arrestin-2 recruitment assay were
transfected with 330 ng receptor construct, 42 ng of a rLuc8
Arrestin3 construct (a renilla luciferase variant fused to β-
arrestin-2) and 800 ng of Membrane Citrulline-YFP constructs.
A total of 6 µl Lipofectamine R© 2000 was used per well.
Murine 300–19 pre-B cells were grown in RPMI1640
with Ultra-Glutamine supplemented with 10% FCS, 50µM
β-mercaptoethanol (Gibco; LuBioScience, Luzern, Switzerland),
1% v/v Pen/Strep, and 1% non-essential amino acids
(BioWhittaker Lonza; VWR Scientific, Nyon, Switzerland).
A total of 3 × 106 300–19 cells were transfected with 2 µg
plasmid DNA using the Amaxa Cell Line Nucleofector Kit V and
program M-013 (Lonza) and grown for 2 weeks in the presence
of 0.8 mg/ml G418. Bulk cell sorting for high CCR7 surface
expression using an APC-conjugated antibody reacting with
human CCR7 (R&D Systems; Minneapolis, MN; FAB197A) was
performed on a BD FACSAria II cell sorter using the FACSDiva
6 software (BD Biosciences).
Bioluminescence Resonance Energy
Transfer (BRET) Assays for G Protein
Signaling and β-Arrestin-2 Recruitment
One day after transfection CHO-k1 cells were washed in PBS
before resuspension in 3mL PBS with glucose (5mM). Cells were
aliquoted [85 µl (without forskolin) or 80 µl (with forskolin
for G protein signaling)] in 96-well plates and incubated with
coelenterazine (Nanolight technologies), for a final concentration
of 5µM, and kept dark. Ligands were added in various
concentrations and incubated for 40min before BRET signal was
detected using an Envision plate reader. When used, forskolin
was added 5min after ligands for a final concentration of 10µM.
The BRET signal was calculated as the ratio between the two
detected signals from YFP and Renilla Luciferase:
BRET ratio= YFP (525 nm)/rLuc (480nm).
Surface Expression Analysis
300–19 cells were washed with PBS, incubated for 10min at RT
with monoclonal anti-mouse CD16/CD32 antibody (Fc block)
and then stained for 20min at 4◦C with anti-human CCR7-
APC in staining buffer (PBS + 0.5% FCS, pH 7.4). Unbound
antibody was removed by two washing steps with staining buffer,
and SYTOX Blue (Invitrogen; LuBio) was added as a dead cell
indicator. All samples were filtered (50µM Cup Filcons; BD
Biosciences), measured with an LSRII flow cytometer using the
FACSDiva 6 software, and analyzed with the FlowJo software
(BD Biosciences).
Migration Assay
The capacity of 300–19 cells stably expressing wild-type or
mutant CCR7 to migrate in a CCR7-dependent manner was
measured by an in vitro chemotaxis assay as previously described
(38, 39). Briefly, cells (1 × 105, 100 µl) were seeded in the top
chambers with 5-µmpore size of the Transwells (Corning Costar;
Vitaris). Lower chamber wells contained 600 µl of medium
supplied with increasing concentrations of human CCL19 or
CCL21 (PeproTech; LuBio) or medium without chemokine
(random migration control). The plates were incubated for
3 h at 37◦C, 5% CO2. Filters were removed and migrated
cells in the bottom chamber were collected and acquired for
60 s at high flow rate on an LSRII flow cytometer using the
FACSDiva 6 software (BD Biosciences). The percentage of
specific migration was calculated by dividing the number of cells
migrated to the lower well by the total cell input (100 µl cell
suspension directly added to 500 µl medium without chemokine
in the lower chamber) multiplied by 100 and subtracting
randommigration (always<0.4%) to the lower chamber without
chemokine present. Non-transfected 300–19 cells were used as a
negative control.
Molecular Modeling
Amodel of CCR7 was generated using the X-ray crystal structure
of CCR5 in complex with CCL5 (PDB 4MBS) (40). The N- and C-
termini of CCR7 not covered by the template were not considered
during model generation and the structural waters of CCR5 were
omitted. The models were built using the Full Model Builder of
ICM 3.8-7b (Molsoft L.L.C.) and subsequently refined through
200 steps of all-atomMonte Carlo-minimization.
Statistical Analysis
LogEC50 values were determined by non-linear regression
calculated using the GraphPad Prism software, which was
also used for all statistical calculations. Statistical significances
between dose-response curves were analyzed performing two-
way ANOVA followed by a Bonferroni post-test. ∗∗∗p <
0.001, ∗∗p < 0.01, and ∗p < 0.05, ns indicates non-
significant differences.
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RESULTS
Ligand Bias With Distinct Signaling Profiles
of CCL21 and CCL19
Although selectively acting at the same receptor, the two
chemokines CCL21 and CCL19 display a low sequence homology
with only 30% sequence identity (Figure 1A). It is therefore
interesting to understand how the two chemokines act at the
same receptor, but also how they differentiate. Previous studies
show that CCL19 is a more potent ligand than CCL21 in both
G protein signaling, recruitment of the non-visual arrestins, β-
arrestins, as well as in DC migration assays, whereas CCL21
induces a stronger calcium flux and ERK activation (3, 7).
Recruitment of β-arrestin-2 toward CCR7 has previously been
evaluated using a DiscoverX system (7), where the reporter
system relies on fusion proteins consisting of receptor and
reporter constructs, but here we reevaluate it using a bystander
BRET based assay which relies on the membrane anchoring
of YFP and the recruitment of a β-arrestin-2-luciferase fusion
protein toward the membrane upon receptor activation. A
similar bystander BRET based assay is used to evaluate G
protein signaling, namely the cAMP Camyel (37) sensor-based
assay which can measure changes of intracellular cAMP as
an indicator of e.g., Gαi activity. By using these two similar
assays with the same receptor construct and in the same cell
line we are able to avoid any tissue bias that may occur
between distinct types of reporter assays tested in different
cell types. As expected, CCL21 displays a less potent G
protein signal than CCL19, and hardly induces any β-arrestin-
2 recruitment (Figure 1C). In contrast, CCL19 stimulates both
pathways with higher potencies [logEC50 (±SEM) of −9.4
(±0.09) M and −7.9 (±0.10) M], confirming previous studies
(7). Based on the suggestions of the N-terminus being central
for chemokine signaling we sought to investigate how the
two chemokines’ N-termini contribute to the differences in
signaling profiles.
FIGURE 1 | Endogenous CCL21 and CCL19 and chimeric N-terminal swap ligands. (A) Sequences of CCL21 and CCL19. The secondary structures are marked
below with beta strands identified as arrows and C-terminally alpha helix identified as a sheet. N-term, core domain, and C-terminal domain refer to domains within
the tertiary structure. The 16 N-terminal residues are swapped within (B). Black refers to identical residues in the two sequences, blue refers to positively charged and
red refers to negatively charged. (B) Schematic overview of CCL21, CCL19, and N-terminally swapped chimeras employed in this study, CCL19CCL21N−term and
CCL21CCL19N−term. Blue refers to CCL21-derived residues and red to CCL19-derived residues not to be confused with red and blue in (A). (C) Dose-response
curves of CCL19, CCL21, CCL19CCL21N−term, and CCL21CCL19N−term in G protein signaling (left) and β-arrestin-2 recruitment (right). The signals are obtained by
co-transfecting CHO cells with CCR7 and reporter constructs able to measure intracellular cAMP changes (G protein) or β-arrestin-2 recruitment. Data are measured
as the arbitrary unit BRET ratio and normalized to that of CCL19 within each separate experiment to compensate for inter-assay variations. Signaling in response to
wild type CCL21 and CCL19 are shown as dotted lines, while the curves of chimeric ligands are shown with solid lines and symbols representing mean values
(±SEM). Data are represented as mean values for several independent experiments performed in duplicates (n = 7 for G protein signaling and n = 6 for β-arrestin-2
recruitment). ANOVA has been used to compare the curves of CCL19 and CCL19NCCL21N−term or the curves of CCL21 and CCL21CCL19N−term and asterisks identify
significant differences, while ns refers to no significant changes. (D) Illustrative overview of wild type and chimeric ligand employed in this study with colors as
described in (B).
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G Protein Signaling Is Determined by the
Core Domain of the CCR7 Ligands—Not
N-Terminus
To evaluate the importance of the chemokine N-terminus
of CCL21 and CCL19 with regards to CCR7 signaling we
constructed chimeric ligands in which the 16 first N-terminal
residues are swapped between the two ligands. The swapped
sequences contain both the N-terminus and part of the N-
loop, as the N-loop is known to interact with the proximal
part of the receptor N-terminus and is important for directing
the positioning of the distal chemokine N-terminus. Where
CCL21 is more positively charged in both its N-terminus and
overall, the N-terminus of CCL19 is more negatively charged
(Figure 1A). Swapping of the N-terminal regions gave rise to
two chimeric ligands, CCL21CCL19N−term and CCL19CCL21N−term
(Figures 1B,D). We first tested the two N-terminal swap
chimeras for their ability to activate G protein signaling following
CCR7 stimulation through the BRET based cAMP accumulation
FIGURE 2 | Mutagenesis study of CCR7 showing changes of CCL21 and CCL19G protein signaling by CCR7 mutations. (A) Barplot displaying change of CCL21- or
CCL19-signaling by CCR7 mutations evaluated in a cAMP accumulation assay. Changes are displayed as relative change of efficacy at 100 nM CCL21, or fold change
of potency for CCL19. Colors correspond to colors in (B), where purple identifies mutations impairing both ligands, blue refers to mutations only affecting CCL21, red
refers to mutations only affecting CCL19, and gray identifies mutations with no impact. Three mutations are highlighted, which are also highlighted in (B) and presented
with their dose-response curves in (D). (B) Scatterplot comparing the effect on CCL21 signaling to that of CCL19. Mutations are plotted with their values from (A) and
colored according to the description in (A). (C) Helical wheel of CCR7 with mutations identified according to effect on CCR7 signaling in (A,B). (D) Dose-response
curve of CCR7W114A, CCR7 E193A, CCR7 R209A, and CCR7WT stimulated with CCL21 or CCL19 in a cAMP accumulation assay. Significant differences between
mutant and WT curve analyzed by two-way ANOVA are identified with colored asterisks corresponding to the color of the signaling curve. Data are represented as
mean values (±SEM) of at least three independent experiments performed in duplicates. To compensate for inter-assay variations data have been normalized to
wildtype within each separate experiment before the collection of data. The n value of independent experiments for each mutation can be found in Table 1.
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assay (Figure 1C, left). Where CCL21 induces a weak signal
the CCL19 chimera containing the N-terminus of CCL21,
CCL19CCL21N−term, displayed a fairly strong activation of CCR7,
reaching a saturation of the dose-response curve at 100 nM
chemokine, which was not significantly different from CCL19,
90% (± 7.6%) compared to 92% (± 4.3%) for CCL19. Performing
a t-test showed that the chimeric ligand differed slightly from
CCL19 with a small but significant decrease of potency with
logEC50 values (±SEM) of −9.4 (±0.09) M and −8.9 (±0.13)
M for CCL19 and CCL19CCL21N−term, respectively. In contrast,
the CCL21 chimera containing the N-terminus of CCL19,
CCL21CCL19N−term, induced a weak G protein signal upon CCR7
stimulation, with the dose-response curve actually overlaying
that of CCL21, indicating that the N-terminus does not change
the signal capacity of CCL21. These data suggest that the G
protein signaling is determined by the core domain of the ligands.
β-Arrestin-2 Signaling Is Similarly
Determined by the Core Domain—Not the
N-Terminus of the Chemokine
Given that signaling bias at CCR7 is mainly divided into G
protein signaling and β-arrestin-2 recruitment, we went on to
test the two chimeras’ ability to recruit β-arrestin-2. If the
signaling bias between the two chemokines resides in the N-
terminus, it would be expected that the CCL19CCL21N−term
chimera, containing the N-terminus of CCL21 that hardly
induces any β-arrestin-2 recruitment, would fail to give a
signal. The CCL21CCL19N−term chimera would be expected to
stimulate β-arrestin-2 recruitment similar to CCL19. However,
this was not the case as the CCL21CCL19N−term chimera failed to
induce any β-arrestin-2 recruitment, similar to CCL21, and the
CCL19CCL21N−term chimeric ligand induced a strong β-arrestin-
2 recruitment resembling the strong signal induced by CCL19
(Figure 1C, right). The chimera reached the same signaling
strength at 100 nM chemokine and only seemed to differ from
CCL19 with a change of potency—similar to that which we
showed for the G protein signal of the chimera. Overall, this
suggests that the β-arrestin-2 recruitment is likewise determined
by the core domain of the chemokines.
Differential Docking Modes of CCL21 and
CCL19 to CCR7
To obtain more detailed structural information of the different
docking modes of CCL19 and CCL21, we expanded our
previously published CCR7 mutation library (7) with 13
mutations more focused on the extracellular domains and the
TABLE 1 | Functional analysis of CCR7 mutations.
G protein β-arrestin-2
Residue CCL21 efficacy CCL19 potency CCL19 efficacy
Position Number Efficacy at
100nM ± SEM
Emut -logEC50
(M) ± SEM
FMut Efficacy at
100nM ± SEM
Emut
N-term K50A Dead * (3) 8.5 ± 0.07 13 * (3) 55.6 ± 2.6 44 * (5)
R54A Dead * (3) 7.1 ± 0.07 100 * (3) Dead * (5)
K57A 99 ± 6.4 1 ns (3) 9.2 ± 0.12 2 ns (3) 125.1 ± 13.6 +25 ns (3)
TM1 1.35 L61A 44 ± 2.9 56 * (3) 8.9 ± 0.13 3 * (3) 36.2 ± 3.0 64 * (3)
1.39 Y65A 44 ± 1.5 56 * (4) 9.0 ± 0.08 2 ns (3) 74.8 ± 6.4 25 ns (5)
TM2 2.53 F107A 76 ± 7.4 24 ns (3) 8.9 ± 0.16 2 ns (3) 149.1 ± 14.1 +49 ns (3)
2.60 W114A 32 ± 5.6 68 * (3) 8.0 ± 0.09 13 * (3) 41.7 ± 3.9 58 * (5)
2.63 S117A 68 ± 3.0 32 ns (3) 9.5 ± +0.07 1 ns (3) 139.4 ± 10.3 +29 ns (5)
2.64 A118S 67 ± 4.6 33 ns (3) 9.7 ± 0.07 2 ns (3) 133.5 ± 12.4 +33 ns (5)
TM3 3.26 K130A 42 ± 3.5 58 * (3) 9.0 ± 0.07 7 * (3) 113.6 ± 7.8 +14 ns (3)
3.29 F133A 27 ± 4.5 73 * (4) 8.7 ± 0.17 1 ns (3) 73.6 ± 2.0 26 * (3)
3.33 K137A 43 ± 8.5 57 * (3) 9.2 ± 0.29 3 ns (3) 113.9 ± 4.4 +14 ns (3)
TM4 4.60 E193A 45 ± 8.6 55 * (4) 9.6 ± 0.17 +3 ns (3) 119.7 ± 4.1 +20 * (4)
ECL2 E205A 48 ± 5.3 52 * (4) 9.2 ± 0.09 3 * (3) 56.3 ± 4.7 44 * (3)
R209A 132 ± 8.8 +32 * (5) 8.5 ± 0.14 8 * (5) 54.3 ± 4.9 46 * (5)
TM7 7.32 N305A 53 ± 3.6 47 * (3) 8.6 ± 0.08 4 * (3) 87.2 ± 2.7 13 ns (5)
7.36 Y308A 38 ± 3.4 62 * (3) 9.1 ± 0.15 2 ns (3) 98.9 ± 12.1 1 ns (3)
Signaling values for CCR7 mutations in response to CCL21 or CCL19 analyzed in G protein signaling or β-arrestin-2 recruitment assays normalized to WT signaling. Data are presented in
Figures 2, 4. Residue position refers to the location in CCR7 based on the nomenclature of Ballesteros-Weinstein (41). CCL21G protein signaling and CCL19 β-arrestin-2 recruitment are
compared to WT based on changes of efficacy at maximal agonist concentration used (100 nM), as saturation of signaling curves were not established. Emut describes the percentage
activity of WT, with WT activity reaching 100%. CCL19G protein signaling is compared to WT based on fold change of potency, and Fmut describes the fold change of signaling
potency compared to WT. “ns” refers to a non-significant change of signaling curve while “*” identifies significant changes between dose-response curves analyzed by ANOVA. Data are
represented as mean values (±SEM) of several independent experiments performed in duplicates and always compared to the signaling values of CCR7 wild type run in parallel within
the same experiments. To compensate for inter-assay variations data have been normalized to wild type within each separate experiment before the collection of data. The n number
of independent experiments for each mutation is shown in brackets to the right of Fmut or Emut, (n). Bold values indicate main findings, italic values indicate statistical significance.
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FIGURE 3 | Overview of mutagenesis study, surface expression, and change of CCL21- and CCL19-directed migration by CCR7 mutations. (A) Serpentine structure
of CCR7 with mutations from Figure 2 identified according to effect on CCR7 signaling, purple identifies mutations impairing both ligands, blue refers to mutations
only affecting CCL21, and red refers to mutations only affecting CCL19. Gray shows residue where alanine substitution did not affect signaling. The predicted
24-residues N-terminal signal sequence of CCR7 which is cleaved of from the mature protein (39) is displayed as faded and predicted cleavage site is indicated by a
dotted line. (B) Surface expression levels of CCR7 were analyzed by flow cytometry in 300–19 pre-B-cells stably transfected with CCR7WT, CCR7R54A, CCR7L61A,
CCR7W114A, or CCR7R209A constructs using anti-human CCR7-APC (gated on the live cell population). Data show mean APC fluorescence intensity values (±SEM)
derived from all migration assays performed in (C,D). (C,D) Transwell chemotaxis in response to CCL21 and CCL19 by R54AN−term, L61A1.35, and W114A2.60 (C)
or R209AECL−2 (D). 300–19 cells were allowed to migrate in response to gradient concentrations of chemokines for 180min. Migrated cells were counted and
percentages of specifically migrated cells relative to the input were calculated. Mean values (±SEM) derived from four independent experiments are shown. Asterisks
identify significant differences between WT and the mutant at 10 nM chemokine calculated performing two-way ANOVA. In (C) significance levels are positioned with
L61A at top, followed by W114A (middle), and R54A (bottom).
minor binding pocket of CCR7. All mutations were created
as alanine substitutions and in parallel with the previously
publishedmutations tested for their impact on CCL21 or CCL19-
mediated G protein activation by co-transfecting the mutated
CCR7 construct with the cAMP Camyel sensor (Figure 2A and
Table 1). Comparing the effect of the mutations on CCL21 and
CCL19 signaling (Figures 2B,C) supports the prior findings of a
differential docking mode of the two chemokines in CCR7 (7).
Accordingly, only CCL21, but not CCL19, seems to depend on
interactions within the major binding pocket (F1333.29, K1373.33,
Frontiers in Immunology | www.frontiersin.org 7 September 2019 | Volume 10 | Article 2156
Jørgensen et al. Unraveling Biased Signaling at CCR7
TABLE 2 | Migratory capacity of CCR7 mutations.
CCL21 (10 nM) CCL19 (10nM)
Mutation
(position)
% Specific migration
at 10nM + SEM
% Specific migration
at 10nM + SEM
WT 5.1 ± 0.50 11.6 ± 1.58
R54A (N-term) 0.3 ± 0.37 * −0.1 ± 0.08 *
L61A (1.35) 4.0 ± 0.49 * 7.5 ±1.94 ns
W114A (2.60) 0.6 ± 0.45 * 1.0 ±0.66 *
R209A (ECL2) 10.6 ± 1.00 * 5.0 ± 0.55 *
The specific migration of 300–19 pre-B-cells stably transfected with CCR7 wild type
or mutant constructs in a Transwell migration assay is shown. Data are presented as
the specific migration at 10 nM chemokine, at which concentration both CCL21 and
CCL19 display peak activity, and values represent data presented in Figure 3. The specific
migration is calculated as the percentage of specifically migrated cells relative to the input
and shown as mean values (±SEM) from four independent experiments. Each mutant is
compared to wildtype by ANOVA and asterisks identify significant differences, while “ns”
refers to a non-significant change. Residue position refers to the location in CCR7 based
on the nomenclature of Ballesteros-Weinstein, as shown in Table 1 (41). Bold values
indicate main findings, italic values indicate statistical significance.
E1934.60, and Y3087.32). In contrast, both ligands depend on
residues found within and around the minor binding pocket,
including the proximal part of the N-terminus (K50N−term,
R54N−term, L611.35, and W1142.60 important for both ligands
and Y651.39 only important for CCL21) (Figures 2, 3A). The
tryptophan in top of TM2 (W1142.60), important for both ligands,
is conserved in more than 80% of chemokines, while a non-
polar aromatic residue is only present in less than 15% of
non-chemokine class A receptors (analyzed by GPCRdb.org).
The dependency of both CCL21 and CCL19 on Trp2.60 is
interesting as it has been deemed important in both CCR5
and CXCR4 for initial chemokine-receptor interactions (23–25).
The extracellular part of CCR7 was shown to be important
for signaling of both chemokines with the N-terminal K50 and
R54 residues being central for signaling (Figure 2B). In general,
all mutations reached a plateau in their dose-response curves
for CCL19 with efficacies similar to that on WT CCR7 (not
shown), indicating that signaling changes could not be attributed
to differential surface expression. Only R54A did not reach the
efficacy of WT, yet this was due to severely impaired signaling
as this mutant displayed surface expression levels similar to WT
(Figure 3B). Looking at migration, a biologically more relevant
readout, the effect the mutations had on G protein signaling
(Figures 2A,B and Table 1) corresponded well with their effect
on migration capacity of 300–19 pre-B cells stably expressing
similar levels of either WT or mutant forms of CCR7 on the cell
surface, shown by the three mutations L61A, W114A, and R54A
(Figures 3B,C andTable 2). In a Transwell migration assay, three
different concentrations of CCL19 and CCL21 were tested (1,
10, and 100 nM) where both ligands showed peak activity at
10 nM for WT CCR7. This peak was reduced significantly for
the two mutations W114A2.60 and R54AN−term both showing
a major impairment of G protein signaling (Table 2). The
L61A1.35 mutation reduced the peak at 10 nM slightly for CCL19,
corresponding to the minor impact it had on G protein signaling
for both ligands.
Mutations in ECL-2 Differentially Impair
CCL21 and CCL19
With extracellular events at CCR7 seeming pivotal for differential
chemokine interaction (as the core domain determined the
difference between CCL21 and CCL19), it was interesting to
identify that alanine substitution of R209 had the opposite effect
on the two ligands (Figures 2B,D). The residue is located in
the extracellular loop 2 (ECL-2), a receptor region of general
importance for ligand recognition in GPCRs (42–44). In more
details, R209 is located in ECL-2A, adjacent to the conserved
cysteine (Cys-1) (Figure 3A). Upon the alanine substitution,
an 8-fold decrease in the potency of CCL19 was observed
(Figure 2D and Table 1). In contrast, signaling in response
to CCL21 was improved with the signaling curve shifting
significantly to the left (Figure 2D). In contrast to the positive
R209 that appeared to be important for CCL19, the alanine
substitution of the negatively charged E205ECL−2 seemed to
have a more profound effect on CCL21 signaling than CCL19
(Figure 2), with a subtle 3-fold decrease of CCL19 potency, but a
50% decrease of CCL21 efficacy (Table 1). Together these studies
suggest that CCL21 and CCL19 might interact differentially with
the extracellular part of CCR7, especially ECL-2. The impact of
the R209A mutation in CCR7 was also tested in the migration
assay (Figure 3D and Table 2). Again, we observed that CCL19-
mediated cell migration was selectively impaired by the R209A
substitution, whereas the migration response to CCL21 was
improved. Both ligands displayed peak activity at 10 nM, where
the activity for CCL19 at this concentration was reduced to 42%
(±20%) of WT while CCL21 was increased 2.5-fold compared to
WT. This indicates that the differential ECL-2 interactions of the
two chemokines are important for normal cell physiology.
Top of TM3 Involved in Biased Signaling
Through our mutagenesis study, we also wished to identify
residues of selective importance for the two signaling pathways:
G protein signaling and β-arrestin-2 recruitment. Since CCL21
hardly induces any β-arrestin-2 recruitment, we only screened
the mutants for their impact on CCL19-stimulated β-arrestin-
2 recruitment and compared this to their impact on CCL19-
stimulated G protein signaling (Figures 4A,B and Table 1). The
impact on β-arrestin-2 recruitment resembled the effect the
mutations had on G protein signaling. One mutation K130A3.26,
however, stands out. Alanine substitution of K130, located in
the top of TM3 adjacent to the conserved cysteine (Cys+1)
(Figure 4C), resulted in an impairment of G protein signaling
without impairing β-arrestin-2 recruitment—if anything it
increased β-arrestin-2 recruitment, although not significantly
(Figure 4D). To understand the role of K1303.26 we constructed
a homology model of CCR7 based on the X-ray structure of
the human CCR5 chemokine receptor (40). From this model,
we see that K1303.26 projects away from the binding pocket
not likely to be involved in direct ligand-interactions (Figure 5).
Interestingly, this residue is located in an area previously shown
to be G protein-specific (20) or important for chemokine receptor
signaling in general (42). Our model also allowed us to look
into the positioning of W114 (the conserved Trp2.60), which
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FIGURE 4 | Mutagenesis study of CCR7 showing changes of CCR7G protein or β-arrestin-2 recruitment upon CCL19-stimulation. (A) Barplot displaying change of
β-arrestin-2 recruitment or G protein signaling by CCR7 mutations evaluated in the BRET based assays. Changes are displayed as relative change of efficacy at
100 nM CCL19, or fold change of CCL19 potency. Colors correspond to colors in (B), where purple identifies mutations impairing both pathways, green refers to
mutations improving signal, red refers to mutations only affecting one signaling pathway and gray identifies mutations with no impact. The mutation K130A3.26
selectively impairing G protein signaling is highlighted. (B) Scatterplot comparing the effect on signaling pathways. Mutations are plotted with their values from (A) and
colored according to the description in (A). (C) Helical wheel showing the location of K1303.26 in CCR7. (D) Dose-response curve of K130A3.26 stimulated with
CCL19 in G protein signaling assay (left) and β-arrestin-2 recruitment assay (right). Statistical differences between K130A and WT curves are analyzed by ANOVA and
significant differences identified by asterisks. Data are represented as mean value (±SEM) of at least three independent experiments performed in duplicates. To
compensate for inter-assay variations data has been normalized to wildtype within each separate experiment before the collection of data. The n value of independent
experiments can be found in Table 1.
projects from TM2 into the binding pocket. We found that R54
(highly important for both ligands and located at the TM1:N-
terminal interface), projects across the binding pocket above
W114, indicating that it could be involved in the process by
which the ligands reach this residue. Our model further suggests
that R54 might engage in unusual stacking with R209 in ECL-
2, together forming a lid over the binding pocket (Figure 5B).
Exploring our model further we found that K1303.26 is located
near ECL-2, partly constrained by its proximity to the TM3-
ECL-2 disulfide (C1293.25–C210ECL−2), and we propose that
K1303.26 may make long-range charge-charge interactions with
D198ECL−2 (Figure 5A). These suggestions are interesting taking
our findings of R209A, also located in ECL-2, into account.
K1303.26 and D198ECL−2 might function as a structural link
between the R209ECL−2 situated on top of the binding pocket
and the extracellular TM3-TM4 region shown to be important
for signaling in other chemokine receptors (42). If true, it
could indicate how the different ligand interactions with ECL-2
could be transmitted to different CCR7 signaling profiles of the
two chemokines.
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FIGURE 5 | CCR7 homology model. (A) Structural link between ECL-2 and extracellular part of TM3 (B) entrance to the minor binding pocket. The CCR5-based
homology model of CCR7 was built in the Molsoft ICM program (PDB ID 4MBS). R54N−term, W1142.60, K1303.26, C1293.25, D198ECL−2, R209ECL2, and
C210ECL−2 are shown in stick representations. Dotted lines represent potential long-range charge-charge interaction between K1303.26 and D198ECL−2.
DISCUSSION
In the current study, we investigate the interactions displayed
between the chemokine receptor CCR7 and its two ligands,
CCL21 and CCL19, with the aim of understanding how they
lead to differential signaling profiles of CCR7. Employing
chimeric ligands, where the N-termini are swapped between
CCL21 and CCL19, we identify the chemokine core domain
to be the determining factor for their differential activation
of CCR7, highlighting the importance of extracellular ligand-
receptor events. Our studies also identify extracellular receptor
interactions, in particular ECL-2, as important for differential
ligand interactions.
The Core Domains of CCL19 and CCL21
Determine Their Differential Signaling
Profiles
For both chemokine chimeras employed in this study, we find
that the core domain determines signaling outcome as the
chimeras resembled the chemokine with which they share the
core domain. The CCL19 chimera containing the N-terminus of
CCL21, CCL19CCL21N−term, resembled CCL19 more than CCL21
in both G protein signaling and β-arrestin-2 recruitment assays,
whereas the other chimera CCL21CCL19N−term resembled CCL21.
The slight decrease of potency when changing the N-terminus
of CCL19 with that of CCL21 corresponds to a previous study
describing that the only N-terminal residue within CCL19 crucial
for its signaling at CCR7 is D7 which is also found within CCL21.
Alanine substitution of the additional N-terminal residues only
showed a minor impact on CCL19 signaling potency (45). This
study indicated that D7 might be central for CCR7 activation
in general, but that no N-terminal residue as such is involved
in ligand specificity between CCL21 and CCL19, corresponding
to the findings within our current study. These findings are also
in accordance with another study showing that the viral US28
GPCR is quite independent of ligand N-terminal sequences for
chemokine signaling but seems to simply rely on the N-terminus
as a steric bulk in the orthosteric binding pocket (46).
Our current study does not disregard the importance of the
N-terminus for signaling, we merely show that at CCR7 the
specific N-terminal sequence of CCL21 and CCL19 does not
dictate their biased signaling patterns. From the crystal structures
of CXCR4:vMIP-II (28) and US28:CX3CL1 (27) it seems that
different receptor-ligand structures display distinct orientations
at the receptor-ligand interface with ligands positioned to interact
with different receptor domains (32). Where one ligand can be
positioned ideally to interact with ECL-2 though its 30s-loop
(CX3CL1), corresponding to a CRS1 recognition, another ligand
can be positioned to interact with ECL-2 through its N-terminus
(vMIP-II), corresponding to a CRS2 recognition. A study of
the core domain of CXCL8 showed that mutating an important
sequence in the 30s-loop modulated the chemokine N-terminus
and N-loop through intramolecular interactions which affected
activation of its two receptors CXCR1 and CXCR2 differentially
(47). Taken together these studies emphasize that the chemokine
core can be important for directing the positioning of the
chemokine N terminus and that the core domain may regulate
the interactions displayed between chemokine andmain receptor
binding pocket. The structure of CCR5:CCL5 also shows that
domains in the globular chemokine core dock deeper into
the binding pocket than first assumed (26), showing that the
core domain of CCL5 is important for more than a simple
tethering function.
Differences of chemokine orientation resulting from
interactions between the core domain and extracellular part
of the receptor and the direct interactions displayed between
the chemokine core domain and the receptor-binding pocket
emphasize the importance of the core domains in chemokines.
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FIGURE 6 | Signaling events at CCR7 rely on core domain interactions and
ECL-2 of CCR7. (A) Chemokine cores determine differential signaling by
CCL21 and CCL19. Chemokines containing the core of CCL19 display G
protein signaling and β-arrestin-2 recruitment, whereas chemokines containing
the core of CCL21 display G protein signaling but fail to recruit β-arrestin-2. (B)
The current mutagenesis study of CCR7 shows that especially the extracellular
events are important for chemokine signaling at CCR7, and the figure
highlights ECL-2, which was found to play an important but differential role
during interactions with the two chemokines. (C) The current study also found
a lysine in TM3, K1303.26, to be important for regulating signaling, as the
alanine substitution of this residue selectively impaired G protein signaling while
not showing an effect on β-arrestin-2 recruitment upon CCR7 stimulation.
Together, this challenges the paradigm of chemokine signaling
residing in the N-terminus. Docking of the N-terminus may
be necessary for signaling initiation, but our studies of CCR7
indicate that it may be more in form of the presence of a steric
bulb, as shown for US28 (46), and that the disparity in signaling
patterns between CCL21 and CCL19 is instead attributed to
differences in the chemokine core domains (Figure 6A).
Identification of Differential Interaction
Modes at CCR7
After finding the core domain to be pivotal for ligand
differences it is interesting to identify a mutation in the
extracellular part of CCR7 with differential impact on the
two chemokines (Figure 6B). Thus, by mutating the centrally
located charged R209 in ECL-2 to alanine an impairment of
CCL19 signaling was observed concomitant with an improved
signal of CCL21. The fact that chemokines acting at the
same receptor may utilize the extracellular domains of the
receptor differentially has also been described for CXCR2.
Here the three ligands CXCL1, CXCL7, and CXCL8 showed
differential interaction modes with the receptor’s extracellular
domains, with an example being that the receptor N-terminus
was important for CXCL1 and CXCL8, but not CXCL7
(48). Studies with CCR5-CCR2 chimeric receptors also stress
the importance of the extracellular domains for chemokine-
mediated signaling, by showing that transferring all extracellular
domains of CCR2 to CCR5 is both necessary and sufficient for
ligand recognition and signaling initiation of CCR2-targeting
chemokines (49).
Where CCR7 has previously been shown to display a
CCL21-specific domain at the TM4-TM5 interface (7), no such
CCL19-specific area has been identified. In our study, we only
identified one residue R209ECL−2 [among 17 tested (Table 1)]
to be selectively important for CCL19 signaling. In general,
CCL19 signaling was predominately affected by mutations in
the extracellular domains of CCR7 with alanine substitutions of
K50N−term, R54 N−term, and R209ECL−2 having a big impact on
CCL19-signaling suggesting that important interactions between
CCL19 and CCR7 are extracellular (Figure 6B). Following these
lines it is interesting to note the potential stacking of R54N−term
and R209ECL−2 observed in our CCR7 homology model, forming
a lid over the binding pocket. This lid might control the entrance
of CCL21 and CCL19 into the binding pocket and engagement
with the conserved Trp2.60, but with different contributions of
these residues as both CCL21 and CCL19 are highly impaired
by R54A, but CCL21 is not by R209A. The importance of ECL-
2 is also seen within the group of lipid prostanoid GPCRs,
such as the prostaglandin EP4 receptor (50), the prostanoid
EP3 receptor (51) and the thromboxane A2 receptor (52),
where the extracellular loop 2 is important for enclosing the
ligand binding site. Similar to the current study, the ECL-2
of the prostanoid GPCRs was found to be central for ligand
interactions as alanine substitution of central ECL-2 residues
diminished ligand signaling in the EP4 and EP3 receptors
(50, 51).
Linking ECL-2 Interactions With CCR7
Signaling
A single residue located in TM3 was identified to be of potential
importance for biased signaling at CCR7. Alanine substitution
of this residue, K1303.26, impaired the G protein activation
without affecting β-arrestin-2 recruitment (Figure 6C). This
finding corresponds to biased areas identified in other class A
GPCRs, such as GPR183, where TM3 was also identified as an
important area for controlling G protein but not β-arrestin-
2 signaling (20). It would be interesting if a distinct area of
CCR7 could be identified as important for controlling β-arrestin-
2 recruitment as seen with TM5 in CCR5 (19). Understanding
the molecular mechanisms driving biased signaling is central
for the development of more specific drugs targeting one
Frontiers in Immunology | www.frontiersin.org 11 September 2019 | Volume 10 | Article 2156
Jørgensen et al. Unraveling Biased Signaling at CCR7
among several signaling pathways to minimize the off-target
effects when aiming at complex and promiscuous receptors
such as in the chemokine system (4). The use of biased
drugs is pursued not only within chemokine receptors but also
in other non-chemokine GPCRs for better clinical outcomes
(53, 54). Our homology model also suggested that K1303.26
may engage in long-range charge-charge interactions with
D198ECL−2. On one hand, this is in line with observations
from the chemokine receptor CCR8 where similar interactions
between ECL-2 and an aromatic cluster in the TM4-TM5
region were identified to be important for receptor activity
(42). On the other hand, it is possible to speculate whether
the differential interaction of CCL21 and CCL19 with ECL-
2 could be transmitted through D198ECL−2-K1303.26 resulting
in a differential degree of receptor activation by the two
ligands and, to some degree, explain the differential ligand
signaling profiles.
CONCLUSION
We identify the core domain of CCL21 and CCL19 to be a
determining factor for their differential activation of CCR7,
highlighting the importance of extracellular ligand-receptor
events. The importance of extracellular receptor interactions are
also underlined through our mutagenesis study, showing that
especially ECL-2 of CCR7 seems important for differential ligand
interactions. Furthermore, we propose a potential link between
ECL-2 and the transmembrane domains, utilized differentially
by the two chemokines. We do not disregard the importance
of chemokine N-terminus docking into the receptor binding
pocket, but our data suggest that the chemokine N-terminus
in broad terms function as a steric bulb more than by
specific residues being a determining factor of differential ligand
signaling. Where small molecules are found to dock deep and
be embedded in the receptor binding pocket, we suggest more
focus should be given to extracellular receptor regions in order
to understand the larger peptide chemokines, both in terms of
ligand-receptor interactions, but also for future modulation of
differential chemokine interactions and differential chemokine-
mediated receptor signaling.
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